Related Experiment Video
Updated: Feb 20, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Looking into cognitive impairment in primary-progressive multiple sclerosis
M Petracca1,2, J Sumowski1, M Fabian1
1Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Retinal atrophy, specifically the ganglion cell + inner plexiform layer (GCIPL), can predict cognitive decline in primary-progressive multiple sclerosis (PP-MS). This non-invasive measure offers a practical alternative to brain volume computation for monitoring neurodegeneration.
Area of Science:
- Neuroscience
- Ophthalmology
- Radiology
Background:
- Cognitive impairment in primary-progressive multiple sclerosis (PP-MS) is linked to brain atrophy.
- Brain volume computation is resource-intensive and not widely available clinically.
- Retinal atrophy metrics may serve as a proxy for gray matter atrophy in PP-MS.
Purpose of the Study:
- To investigate the predictive role of retinal atrophy metrics on cognitive decline in PP-MS.
- To assess optical coherence tomography (OCT) metrics as potential indicators of neurodegeneration.
- To explore the mediating role of gray matter atrophy in the relationship between retinal measures and cognition.
Main Methods:
- Twenty-five PP-MS patients underwent OCT and 3.0-T MRI.
- Cognitive function was assessed using the Brief International Cognitive Assessment for Multiple Sclerosis.
- Stepwise logistic regression analyzed OCT metrics (retinal nerve fiber layer, GCIPL, macular volume) for prediction of cognitive impairment.
Main Results:
- Ganglion cell + inner plexiform layer (GCIPL) thickness was associated with and predictive of cognitive impairment (P=0.036).
- GCIPL correlated with normalized brain volume (P=0.047) and thalamic volume (P=0.001).
- Thalamic volume showed a near-mediating effect between GCIPL and cognitive scores (P=0.063).
Conclusions:
- GCIPL thickness is a valid indicator of neurodegeneration in PP-MS.
- GCIPL offers higher specificity for neuronal loss compared to brain atrophy.
- GCIPL provides a non-invasive, quantitative method for monitoring cognitive impairment related to neuronal loss in PP-MS.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Development During Adulthood
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Parkinson's Disease: Overview
Role of Cerebellum and Prefrontal Cortex in Memory
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

